Search

for
Search:

Did you mean Patient-Reported Outcome Measures?

GlossaryPatient-Reported Outcome Measures

tools for patients to report their health and treatment outcomes

Patient-Reported Outcome Measures (PROMs) are tools used to gather information directly from patients about their health status, quality of life, and the effectiveness of treatments from their perspective. These measures are crucial in both clinical practice and research as they provide insights into how patients feel and function, which can help guide treatment decisions and improve healthcare outcomes.

Related Terms

Sort by

Research

30 / 1000+ results

Development of Clinician-Reported Outcome and Patient-Reported Outcome Measures for Eyebrow, Eyelash, and Nail Assessment in Alopecia Areata

research Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) Measures for Eyebrow, Eyelash and Nail Assessment in Alopecia Areata

56 citations , August 2020 in “American Journal of Clinical Dermatology”

New tools help assess eyebrow, eyelash, and nail changes in Alopecia Areata, improving understanding of patient experiences.

research Patient-reported outcome assessment and objective evaluation of chemotherapy-induced alopecia

8 citations , February 2018 in “European journal of oncology nursing”

The Hair Check tool can measure hair loss, but patients' own reports are more reliable for assessing hair loss during chemotherapy.

research Patient-reported outcome improvements following scalp hair regrowth among patients with Alopecia Areata: analysis of the ALLEGRO-2b/3 trial

3 citations , February 2025 in “Journal of Dermatological Treatment”

Hair regrowth in Alopecia Areata patients leads to increased satisfaction and reduced stress.

research Concordance between clinician-reported and patient-reported outcomes of eyebrow and eyelash hair loss in patients with severe alopecia areata: Results from BRAVE-AA1 and BRAVE-AA2 studies

2 citations , June 2024 in “Journal of the American Academy of Dermatology”

Patients and clinicians generally agree on eyebrow and eyelash hair loss improvements in severe alopecia areata.

research Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer

1 citations , July 2021 in “Frontiers in Oncology”

Neoadjuvant endocrine therapy led to a better future outlook than chemotherapy, with no major quality of life differences.

research Patient-reported outcomes following various incision techniques in breast reconstruction: an observational cohort study in China

November 2025 in “Journal of Cancer Research and Clinical Oncology”

Endoscopic-assisted surgery leads to higher patient satisfaction in breast reconstruction.

Patient-Reported Outcomes of Adverse Events After Perioperative Chemotherapy for Breast Cancer: A Prospective Observational Study

research Patient-reported outcomes of adverse events after perioperative chemotherapy for breast cancer: A prospective observational study

October 2025

Some side effects of breast cancer chemotherapy last longer than others, and patient feedback can help improve care.

Patient-Reported Outcomes, Provider-Reported Outcomes, And Physiologic Parameters After Gender-Affirming Hormone Treatment In Canada: A Systematic Review

research Patient-reported outcomes, provider-reported outcomes, and physiologic parameters after gender-affirming hormone treatment in Canada: a systematic review

January 2025 in “HORMONES”

Gender-affirming hormone treatments need better patient-focused outcome measurements and standardized data collection.

Patient-Reported Outcomes of Topical Finasteride/Minoxidil Treatment for Male Androgenetic Alopecia: A Retrospective Study Using Telemedical Data

research Patient‐reported outcomes of topical finasteride/minoxidil treatment for male androgenetic alopecia: A retrospective study using telemedical data

May 2024 in “Journal of cosmetic dermatology”

Topical finasteride/minoxidil is effective but not better than oral finasteride for hair loss.

research PSS21 GAP ANALYSIS FOR PATIENT-REPORTED OUTCOMES MEASURES FOR ALOPECIA

May 2011 in “Value in Health”

No current patient-reported outcome measure fully meets FDA requirements for alopecia treatments.

research Development and validation of a patient‐reported outcome measure for hair loss treatment: The HAIR‐Q

2 citations , July 2024 in “Journal of Cosmetic Dermatology”

The HAIR-Q is a reliable tool for assessing patient satisfaction with hair loss treatments.

research An Evaluation of Generic and Disease‐Specific Patient‐Reported Outcome Measures to Assess the Impact of Percentage of Scalp Hair Loss on Health‐Related Quality of Life in a European Population

1 citations , January 2025 in “JEADV Clinical Practice”

Disease-specific tools better assess alopecia areata's impact on quality of life.

Patient-Reported Outcomes and Safety of Direct-to-Consumer Teledermatology for Finasteride in Male Androgenetic Alopecia

research Patient-reported treatment outcomes and safety of direct-to-consumer teledermatology for finasteride treatment in male androgenetic alopecia: A cross-sectional study

January 2023 in “DIGITAL HEALTH”

Most men using teledermatology for hair loss treatment saw improved hair and self-esteem, with some experiencing side effects.

Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The Allegro Phase 2b/3 Randomized Clinical Trial

research Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial

4 citations , October 2024 in “American Journal of Clinical Dermatology”

Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.

Patient-Reported Outcomes for Scalp, Eyebrow, and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from Two Phase 3 Clinical Trials

research 52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical Trials

September 2024 in “Journal of the American Academy of Dermatology”

Baricitinib helps long-term hair regrowth in severe alopecia areata patients.

research Evaluating the accuracy of patient-reported hair outcomes versus trichometric measurements in PRP therapy

May 2025 in “Archives of Dermatological Research”

Patient-reported hair improvements align with actual hair density changes, not hair width.

research Patient and Clinician‐Reported Outcomes and Adherence to Calcipotriene/Betamethasone Dipropionate PAD‐Cream in Treatment of Scalp Psoriasis in Adults: An Interim Analysis of the PRO‐SCALP Study

May 2025 in “JEADV Clinical Practice”

The cream effectively treats scalp psoriasis, improving symptoms and quality of life, with high patient satisfaction.

research A systematic review of patient‐reported outcomes in patients with cutaneous lupus erythematosus

18 citations , July 2016 in “British Journal of Dermatology”

Cutaneous lupus erythematosus greatly reduces patients' quality of life.

research 532P Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011)

2 citations , September 2022 in “Annals of Oncology”

Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.

Safety and Patient-Reported Outcomes in Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Treated With CDK4/6 Inhibitors in China: A Cross-Sectional Study

research Safety and patient-reported outcomes in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with CDK4/6 inhibitors in China: A cross-sectional study.

June 2024 in “Journal of Clinical Oncology”

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.

research Generic vs. Disease-Specific Patient Reported Outcome (PRO) Instruments for Assessing HRQoL Burden Among Patients Diagnosed with Alopecia Areata: Evidence from TARGET-DERM AA

November 2024 in “SKIN The Journal of Cutaneous Medicine”

Disease-specific tools better assess quality of life in alopecia areata patients.

Choice of Recall Period for Patient-Reported Outcome Measures: Criteria for Consideration

research Choice of recall period for patient-reported outcome (PRO) measures: criteria for consideration

82 citations , September 2011 in “Quality of Life Research”

Choosing the right recall period for patient feedback is important for accurate data and depends on the disease, symptom changes, and patient impact.

research The Spectrum of Health Domains Important to Lupus Patients Early Development of a Disease Activity Patient Reported Outcome.

2 citations , March 2019 in “PubMed”

A new tool helps lupus patients and doctors better track symptoms and quality of life.

research Efficacy, safety, and patient-reported outcomes of scalp micropigmentation in scarring alopecia

September 2025 in “Journal of Cutaneous and Aesthetic Surgery”

Scalp micropigmentation improves appearance and satisfaction in scarring alopecia but may require repeat sessions.

research 0475 High-dose UVA-1 therapy improves patient-reported outcomes and clinical scores in patients with sclerosing skin disease

July 2025 in “Journal of Investigative Dermatology”

High-dose UVA-1 therapy improves symptoms and skin condition in sclerosing skin disease.

research 43364 Long Term Real-World Patient-Reported Outcomes with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry

September 2023 in “Journal of the American Academy of Dermatology”

research Analysis of alopecia areata surveys suggests a threshold for improved patient-reported outcomes

14 citations , June 2022 in “British Journal of Dermatology”

A SALT score of ≤ 20 indicates meaningful improvement in alopecia areata treatment.

Developing Patient-Reported Outcome Measure for Hair and Skin Disorders

research A qualitative phase I study protocol on developing patient-reported outcome measure for hair, scalp, eyebrows, eyelashes, and beard-related skin disorders

August 2022 in “medRxiv (Cold Spring Harbor Laboratory)”

The goal is to create a tool for patients to report their experiences with various hair and scalp disorders.

research A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes

November 2025 in “Journal of Clinical Medicine”

Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.

The Efficacy of Baricitinib as a Treatment Option for Alopecia in Terms of Promoting Hair Regrowth and Improving Patient Reported Outcomes

research The Efficacy of Baricitinib as a Treatment Option for Alopecia, In Terms of Promoting Hair Regrowth and Improving Patient Reported Outcomes

May 2024

Baricitinib effectively promotes hair regrowth in severe alopecia with minimal side effects.